CSL posts US$2.6 billion statutory loss for year to 30 June 2026 despite US$15.8 billion revenue
AI مارکیٹ کا خلاصہ
CSL reported FY26 revenue down 1% and underlying NPATA down 2%, while heavy one-off restructuring charges and US$7.1bn pretax impairments drove a US$2.6bn statutory loss. Although management framed FY26 as a reset year and reiterated steady FY27 revenue with modest underlying profit growth, the scale of impairments and continued pressure in Vifor from generics/regulation may weigh on broader risk appetite toward healthcare and Australian equities in the near term.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT-0.05%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
▼ Bearish
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
CSL reported full-year results for the year ended 30 June 2026, with revenue of US$15.8 billion down 1% and underlying NPATA of US$3.1 billion down 2%. The company recorded a statutory net loss after tax of US$2.6 billion, citing significant one-off costs and impairments. CSL kept its final dividend unchanged at US$1.62 per share and said it completed a A$1 billion share buyback. It also disclosed US$799 million of restructuring costs tied to the integration of its Behring and Vifor operations.
